
Adjuvance co-founder David Gin describes the clinical use of QS-21 as an adjuvant in developing and enhancing cancer vaccines.
Gin_slovin_nihms600845Empowering health.
Adjuvance co-founder David Gin describes the clinical use of QS-21 as an adjuvant in developing and enhancing cancer vaccines.
Gin_slovin_nihms600845